Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2951 to 3000 of 4090 results for patient

  1. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

    NICE guideline
    Last updated
    19 March 2024
    View recommendations

    Sections for NG195

  2. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    31 August 2022
    View recommendations

    Sections for TA820

  3. Myocardial infarction: medication for MI in preceding 12 months (IND125)

    This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79

    General practice indicators suitable for use outside of QOF
    Last updated
    9 November 2020

  4. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]

    Awaiting development Reference number: GID-TA11748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]

    Awaiting development Reference number: GID-TA11754 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

    Awaiting development Reference number: GID-TA11383 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]

    Awaiting development Reference number: GID-TA11608 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]

    Awaiting development Reference number: GID-TA11417 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

    Awaiting development Reference number: GID-TA11507 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Retatrutide for managing overweight and obesity [ID6644]

    Awaiting development Reference number: GID-TA11845 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]

    Awaiting development Reference number: GID-TA11673 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development Reference number: GID-TA11360 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  17. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  18. Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]

    Awaiting development Reference number: GID-TA11753 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]

    Awaiting development Reference number: GID-TA11825 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]

    Awaiting development Reference number: GID-TA11575 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  23. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [ID6759]

    Awaiting development Reference number: GID-TA11551 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development Reference number: GID-TA11363 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  33. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development Reference number: GID-TA11300 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  35. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development Reference number: GID-TA11216 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  36. Delgocitinib for Chronic Hand Eczema [ID6688]

    Awaiting development Reference number: GID-TA11777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]

    Awaiting development Reference number: GID-TA11870 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]

    Awaiting development Reference number: GID-TA11868 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  40. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

    Awaiting development Reference number: GID-TA11769 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]

    Awaiting development Reference number: GID-TA11741 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]

    Awaiting development Reference number: GID-TA11879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  43. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  44. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]

    Awaiting development Reference number: GID-TA11641 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  45. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development Reference number: GID-TA11326 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

    Awaiting development Reference number: GID-TA11065 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  47. Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]

    Awaiting development Reference number: GID-TA11872 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  48. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development Reference number: GID-TA11218 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  49. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development Reference number: GID-TA11161 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  50. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development